Telavancin is a dual action, bactericidal lipoglycopeptide. Its in vitro activity was compared with vancomycin and linezolid against 392 Gram-positive isolates from cancer patients. MIC 90 values (lg ml À1 ) for telavancin, vancomycin and linezolid were determined for methicillin-susceptible Staphylococcus aureus (MSSA), methicillin-resistant S. aureus (MRSA), methicillin-susceptible (MS), methicillin-resistant (MR), coagulase-negative staphylococci (CoNS), viridans group streptococci (VGS), Streptococcus pneumoniae, Bacillus species, Corynebacterium species and Micrococcus species. Telavancin had potent activity against b-hemolytic streptococci and Staphylococcus lugdunensis. Whereas 100% of MRSA and 98% of MSSA had vancomycin MICs X1.0 lg ml À1 (minimum inhibitory concentrations (MICs) at which poor clinical responses have been reported), the highest telavancin MIC was 0.38 lg ml À1 . For CoNS, 95% of MS and 100% of MR isolates had vancomycin MICs X1.0 lg ml À1 , whereas the highest telavancin MIC was 0.38 lg ml À1 . Furthermore, 48% of VGS had vancomycin MICs X1.0 lg ml À1 , whereas the highest telavancin MIC was 0.064 lg ml À1 . A similar pattern was noticed for S. lugdunensis, Bacillus species, Corynebacterium species and b-hemolytic streptococci. These data suggest that telavancin and linezolid have potent activity against most Gram-positive organisms that cause infections in cancer patients. Consequently, they may be considered as alternatives to vancomycin, especially in institutions wherein a substantial proportion of infections are caused by organisms with vancomycin MICs X1.0 lg ml À1 .
INTRODUCTION
Infections occur frequently in cancer patients, especially in those with hematologic malignancies and profound neutropenia, but also in patients with solid tumors and with adequate neutrophil counts. Although geographic and institutional variations are known, Grampositive organisms remain the predominant pathogens in this setting globally. 1,2 Staphylococcus species (coagulase-negative staphylococci (CoNS), Staphylococcus aureus) are isolated most often, but a wide spectrum of Gram-positive bacteria such as Enterococcus spp., viridans group streptococci, b-hemolytic streptococci, Bacillus spp., Corynebacterium spp. and Micrococcus spp., are not uncommon. 3, 4 Organisms such as Listeria monocytogenes, Rhodococcus equi and Stomatococcus mucilaginosus are less common, but important pathogens. Occasionally, vancomycin-resistant organisms such as Leuconostoc spp., Lactobacillus spp. and Pediococcus spp. are also encountered.
For decades, vancomycin has been the agent of choice for the treatment of documented Gram-positive infections in neutropenic cancer patients, and has also been recommended by many as empiric therapy, when Gram-positive infections are strongly suspected. 5, 6 These recommendations may now be outdated at several institutions owing to changing susceptibilities and other issues with vancomycin. Many centers are reporting declining vancomycin activity (the minimum inhibitory concentration (MIC) creep), tolerance (MBC X32 times the MIC), and lack of bactericidal activity, especially among staphylococcal isolates. [7] [8] [9] Clinical failures have been reported in staphylococcal infections caused by isolates with vancomycin MICs of 1.0-2.0 mg ml À1 , regarded as vancomycin susceptible. 10 Reports such as these have become frequent, and have led to the lowering of vancomycin-susceptibility/-resistance breakpoints for S. aureus by the Clinical Laboratory Standards Institute (CLSI). 11 A recently published meta-analysis showed that infections caused by S. aureus isolates with vancomycin MICs of 41.5 mg ml À1 were associated with increased mortality irrespective of the source of infection or the MIC-testing method. 12 Other studies have shown that MICs performed using the E-test method are more reliable for predicting treatment response compared with other susceptibility testing methods, although the E-test is considered by some to slightly overestimate the MICs. 13 Consequently, clinical laboratories are now being asked to consider using E-test MIC determination for all MRSA bloodstream isolates. 12, 13 Guidelines for the treatment of MRSA infections recommend that clinical response should determine the administration of vancomycin for isolates with a vancomycin MIC of p2.0 mg ml À1 whereas, for isolates with a vancomycin MIC 42.0 mg ml À1 , an alternative to vancomycin should be used. 14 Agents such as linezolid and daptomycin are considered alternatives but clinical data for these agents in cancer patients is minimal and each agent is associated with some limitations. Telavancin, a novel, dual action lipoglycopeptide, is reported to be rapidly bactericidal against Gram-positive cocci. 15, 16 We believe that this agent might be a potential alternative to vancomycin in neutropenic cancer patients. Consequently, we compared it's in vitro activity to vancomycin and linezolid against recent clinical isolates obtained from cancer patients being treated at our institution (a comprehensive cancer center).
RESULTS
The comparative in vitro activities of telavancin, vancomycin and linezolid against 392 isolates representing at least 15 bacterial species are presented in Table 1 .
Staphylococci
Of the 84 coagulase-negative staphylococcal isolates tested, 7, all Staphylococcus lugdunensis, were identified down to species level. All seven were inhibited by 0.25 mg ml À1 of telavancin which had lower MICs than vancomycin (MIC range, 0.75-1.5 mg ml À1 ) and linezolid (MIC range, 0.38-0.75 mg ml À1 ). Only one isolate was inhibited by o1.0 mg ml À1 of vancomycin. Of the remaining 77 CoNS isolates, 55 (71%) were MR. All 22 MS isolates were inhibited by p0.38 mg ml À1 of telavancin (MIC range, 0.06-0.38 mg ml À1 ). In contrast, 21 of 22 isolates (95%) had vancomycin MICs of X1.0 mg ml À1 (range, 0.75-3.0 mg ml À1 ). All 22 were inhibited by p1.5 mg ml À1 of linezolid (range, 0.5-1.5 mg ml À1 ). Similarly, in all 55 MR-CoNS isolates were inhibited by p0.38 mg ml À1 of telavancin (range, 0.125-0.38 mg ml À1 ), whereas all 55 (100%) had vancomycin MICs of 41 mg ml À1 (range, 1.5-4.0 mg ml À1 ). Fifty of these isolates (91%) were inhibited by p1.5 mg ml À1 of linezolid (range, 0.38-1.5 mg ml À1 ). The five remaining isolates revealed high levels of linezolid resistance, with MICs of X256 mg ml À1 for each isolate.
Of the 106 S. aureus isolates tested, 56(53%) were MSSA. All 56 were inhibited by p0.38 mg ml À1 of telavancin (range, 0.25-0.38 mg ml À1 ), whereas all 56 had vancomycin MICs of X1.0 mg ml À1 (range, 1.0-1.5 mg ml À1 ). The MIC 90 for linezolid against these isolates was 1.5 mg ml À1 (range, 0.75-2.0 mg ml À1 ). All 50 MRSA isolates were inhibited by p0.38 mg ml À1 of telavancin (range, 0.064-0.38 mg ml À1 ), whereas 49 (98%) of these isolates had vancomycin MICs of X1.0 mg ml À1 (range, 0.19-2 mg ml À1 ). All MRSA isolates were inhibited by p2.0 mg ml À1 of linezolid (range, 0.75-2.0 mg ml À1 ).
Streptococci
Telavancin exhibited potent activity against viridans group streptococci, inhibiting all 27 isolates at p0.064 mg ml À1 (range, 0.016-0.064 mg ml À1 ). Vancomycin inhibited 50% of these isolates at p0.75 mg ml À1 , and all 27 at p1.5 mg ml À1 (range, 0.38-1.5 mg ml À1 ). The MIC 90 for linezolid for these isolates was 1.5 mg ml À1 (range, 0.75-2.0 mg ml À1 ). Ten Streptococcus pneumoniae isolates were available for testing. Telavancin had the lowest MICs, inhibiting all ten at p0.064 mg ml À1 (range, 0.012-0.064 mg ml À1 ). All pneumococcal isolates were also susceptible to vancomycin and linezolid. A total of 26 b-hemolytic streptococci (2-Group A; 11-Group B; 13-Group G) were tested. Telavancin exhibited potent activity against these organisms, inhibiting all 26 at 0.25 mg ml À1 . All isolates were susceptible to linezolid and vancomycin as well, but these agents were less potent.
Enterococci
Thirty two Enterococcus faecalis-isolates were tested and were found to be susceptible to all three agents. Telavancin inhibited all 32 isolates at o0.38 mg ml À1 , (which is below the Food and Drug Administration (FDA)-susceptibility breakpoint of p1.0 mg ml À1 ), vancomycin at 3.0 mg ml À1 , and linezolid at 4.0 mg ml À1 . All 32 Enterococcus faecium isolates were resistant to vancomycin (VRE-MICs 4256 mg ml À1 ). Linezolid inhibited 25 isolates (78%) ato4.0 mg ml À1 (range, 1.5-128.0 mg ml À1 ). Although telavancin had lower MICs for these isolates than vancomycin (range, 1.0-16.0 mg ml À1 ), only one isolate was inhibited byp1.0 mg ml À1 .
Other Gram-positive organisms Telavancin had potent in vitro activity against Bacillus spp., Corynebacterium spp. and Micrococcus spp. All Corynebacterium spp. (38 isolates) and all Micrococcus spp. (10 isolates) were also susceptible to vancomycin and linezolid. All 24 Bacillus spp. isolates were inhibited by o1.5 mg ml À1 of linezolid. However only 10 (31%) were inhibited by o1.0 mg ml À1 of vancomycin (range, 0.25-8.0 mg ml À1 ). Telavancin had potent activity against the two Listeria monocytogenes isolates and one Rhodococcus equi isolate available for testing. Linezolid and vancomycin were less active.
Although the significance of isolates with vancomycin MICs of X1.0 mg ml À1 has only been established for S. aureus, and has not been established for telavancin, we determined the proportion of all species tested that had MICs X1.0 mg ml À1 for both agents. These results are shown in Table 2 . We excluded the 32 VRE isolates from this calculation, leaving a total of 360 isolates. Of these, 292 (81%) had vancomycin MICs X1.0 mg ml À1 , including 95% of MS-CoNS isolates, and 100% of MR-CoNS, 86% of S. lugdunensis, 100% of MSSA and 98% of MRSA isolates respectively. The highest telavancin MIC for these isolates was 0.38 mg ml À1 . Additionally, 67% of Bacillus species, 50% of Corynebacterium species, 85% of b-hemolytic streptococci and 48% of viridans group streptococci also had vancomycin MICs X1.0 mg ml À1 . In contrast, only two isolates, both Bacillus spp., had telavancin MICs X1.0 mg ml À1 .
DISCUSSION
Gram-positive organisms remain the predominant bacterial pathogens in cancer patients although some institutions are reporting a resurgence of Gram-negative infections. 1,2 Currently, B80% of bacteremias (including central line-associated bloodstream infections) and B50% of infections at all sites, have a Gram-positive component. CoNS are isolated most often, followed by S. aureus, viridans group streptococci and Enterococcus spp. 17 Other Gram-positive organisms (Bacillus spp., Corynebacterium spp., Listeria monocytogenes, Rhodococcus equi, Micrococcus spp. and Stomatococcus mucilaginosus) are isolated with varying frequency. Consequently, empiric antimicrobial therapy in febrile neutropenic patients needs to provide coverage not just against staphylococci and streptococci, but against a much wider spectrum of Gram-positive pathogens.
Additionally, many of the organisms listed above are resistant to the fluroquinolones and b-lactams, agents that are often used for the prevention and treatment of infections in cancer patients.
Until recently, vancomycin was considered to be the agent of choice for the treatment of Gram-positive infections in patients with cancer. 5 In fact, previous iterations of the Infectious Diseases Society of America (IDSA) guidelines for the management of febrile neutropenic patients recommend the use of vancomycin when such infections are documented. 18 These guidelines also outlined several indications for the empiric use of vancomycin. However, over the past 8-10 years, several reports have been published documenting vancomycin failures in staphylococcal infections caused by organisms considered to be In vitro activity of telavancin KVI Rolston et al susceptible to it, but with MICs X1.0 mg ml À1 . 7, 10 Institutions worldwide, including our own, have documented an upward MIC creep with organisms such as S. aureus still being susceptible based on the revised CLSI-breakpoints, but having MICs of 1.0 mg ml À1 or more. 7, 9, 17 Diminished vancomycin bactericidal activity has been documented against such isolates. These reports have raised concerns that vancomycin may no longer be the agent of choice for the treatment of infections caused by such isolates, especially in neutropenic patients in whom bactericidal agents are generally preferred. 19 Because of these concerns, we conducted a retrospective review of MRSA bloodstream infections in cancer patients treated at our institution between January 2001 and June 2009 and found a high treatment failure rate (52%) for vancomycin. 20 An independent predictor of infection-related mortality was infection by MRSA isolates with MICs of 42.0 mg ml À1 . Based on this experience, we have developed clinical practice guidelines that recommend the use of alternative agents (for example, daptomycin or linezolid) when such infections are encountered in our patients. However, both these agents are associated with limitations, leaving room for the development and evaluation of other agents. Linezolid is bacteriostatic, and is associated with myelotoxicity particularly with prolonged usage, making it less than ideal in patients with hematologic malignancies and recipients of hematopoietic stem cell transplantation. There have also been reports of increasing resistance to linezolid often associated with increased usage. 21 Although daptomycin does not have these limitations, it is inactivated by pulmonary surfactant. A substantial proportion of neutropenic patients (25-35%) develop pulmonary infiltrates precluding the use of daptomycin. Unlike other studies evaluating the in vitro activity of telavancin, our study tested isolates obtained exclusively from patients with cancer, a substantial proportion of which were neutropenic. Our data demonstrate that at our institution, the majority of staphylococcal isolates and a substantial proportion of other Gram-positive isolates have vancomycin MICs X1.0 mg ml À1 . Our data also demonstrate that telavancin and linezolid have potent in vitro activity against most Gram-positive organisms that cause infections in neutropenic patients, including those with vancomycin MICs X1.0 mg ml À1 . 15, 16 Telavancin inhibited all isolates with vancomycin MICs of X1.0 mg ml À1 at a concentration of 0.38 mg ml À1 . These findings are in line with those published by other investigators against isolates from the United States, Europe, Latin America and the Asia-Pacific region. 16, 22, 23 It has potent in vitro activity against streptococci, Bacillus species and Corynebacterium species. It also has better activity than vancomycin against S. lugdunensis which has recently emerged as a significant pathogen in both immunocompetent and immunosuppressed patients. 24 Additionally, telavancin has been shown to possess superior activity compared with vancomycin against multidrug-resistant S. aureus in a range of in vitro biofilm models suggesting that it might be potentially useful in the treatment of biofilm-mediated infections. 25 Although not particularly active by itself against Enterococcus species that are vancomycin resistant (primarily E.faecium), telavancin possesses synergistic activity when combined with rifampin against E. faecium isolates resistant to both linezolid and vancomycin. 26 Telavancin has been extensively evaluated for the treatment of complicated skin and skin structure infections and in 2009 received approval for this indication by the US Food and Drug Administration (FDA). 27 It has also been evaluated for the treatment of adult patients with hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) and received FDA approval for this indication (HABP/VABP caused by susceptible strains of S.aureus when alternative agents are not suitable) in June 2013. 28 Telavancin has been shown to be superior to vancomycin for the treatment of MRSA and glycopeptides-intermediate S. aureus in immunecompromised/neutropenic murine bacteremia models. 29, 30 Although not formally evaluated in neutropenic patients, we believe that with its potent in vitro activity against a wide spectrum of Gram-positive pathogens, its dual mechanism of action (inhibition of bacterial cell wall synthesis and disruption of cell membrane function), and its rapid bactericidal activity, it has a potential play in the treatment of Gram-positive infections in neutropenic patients. Telavancin does have adverse effects including QT c prolongation, infusion-related reactions, and worsening of renal function particularly in patients with pre-existing moderate to severe renal impairment. Its use during pregnancy needs to be avoided unless the potential benefits outweigh the potential risk to the fetus. Nevertheless, with the increasing frequency of some neoplasms in an ageing population, and the use of hematopoietic stem cell transplantation for several indications, we believe that clinical evaluation of telavancin for the treatment of selected infections in neutropenic patients is warranted.
MATERIALS AND METHODS Organisms
The organisms obtained for this study were from clinical cultures submitted to our institutional microbiology laboratory, from patients with various hematologic malignancies and solid tumors, treated between 2012 and 2013. The organisms were obtained for in vitro testing after approval of this study by the Institution Review Board (IRB). To avoid duplication, only one isolate per patient per episode of infection was tested. The majority of these isolates (485%) were from blood culture specimens. A few were from other significant clinical sites such as cerebrospinal fluid, wounds and pleural or synovial fluid.
Susceptibility testing
Susceptibility testing was performed using the E-test methodology in accordance with CLSI guidelines (25) . Appropriate control strains (S. aureus Table 2 The proportion of Gram-positive isolates with vancomycin and telavancin MICs X1.0 lg ml À1 . 
